



Presents for your consideration:

BioProstate

- Supports healthy prostate function
- Encourages healthy testosterone, dihydrotestosterone (DHT) balance
- Supports enhanced control of bladder function
- Supplies targeted nutrition for bladder and prostate tissues

Zinc Aspartate. The prostate contains a higher concentration of zinc than any other organ in the body. The hormone prolactin increases testosterone absorption by the prostate. Excess testosterone stimulation is known to increase the risk of prostate disorders (benign and malignant). Zinc inhibits the enzyme 5-alpha reductase. This enzyme converts testosterone to dihydrotestosterone, the form of testosterone thought to be most responsible for benign proliferative changes to the prostate gland. Zinc supplementation has been shown to reduce the size and symptoms of benign prostate disorders in a majority of patients.

Copper glycinate is added to BioProstate to support zinc and maintain an ideal zinc/copper balance. Copper, along with zinc supports the production of super oxide dismutase, an essential cellular enzyme.

Saw Palmetto Extract (Serenoa Repens): is indicated for prostate complaints and irritable bladder. The free fatty acids, sitosterols, flavonoids and polysaccharides in saw palmetto have been shown to have positive benefits on nocturia, flow rate and residual volume.

BioProstate	Amounts per serving
Serving size	2 veggie capsules
Number of servings per container	60
Zinc (Aspartate)	10 mg.
Copper (Glycinate)	1 mg.
Saw Palmetto Extract (45% fatty acids)	350 mg.
Nettle Leaf Powder (Urtica Dioica)(4:1)	150 mg.
Pygeum Africanum Extract (2.5% sterols)	125 mg.
Pumpkin Seed	80 mg.
Beta-Sitosterol	15 mg.
Lycopene	200 mg.
Suggested Dose: Take 1-2 capsules, twice per day or as directed by your health care professional.	

Nettle Leaf Powder (Urtica Dioica): has been shown to inhibit the enzyme aromatase, which converts testosterone to estradiol. Aromatase, and the resulting higher levels of estradiol have been implicated in the cause (pathogenesis) of benign prostatic hyperplasia.

BioProstate supplies the most complete support available for prostate health. We invite you to compare!

Pygeum Africanum Extract: improved urinary flow, voided urine volume and a reduction in residual urinary volume has been shown in test subjects. Nightly urinary frequency (nocturia) and daytime frequency were also reduced.

Pumpkin Seed & Beta-Sitosterol: Pumpkin seed oil is a rich source of Beta-sitosterol. Administration of pumpkin seed extract/oils or the purified beta-sitosterol may be beneficial for prostate health. Overall prostate scores, urine flow and prostate volume improved during therapy in some studies.

Lycopene: is a carotenoid that may protect humans from certain disorders such as disorders of the prostate. Lycopene may have anticarcinogenic and antiatherogenic activities. Lycopene has antioxidant protective properties.

References:

Gyorkey F et al. **Zinc and magnesium in human prostate glands.** *Cancer Res* 27:1348-53, 1967.

Gyorkey F, Sato CS. **In vitro zinc-binding capacities of normal, hyperplastic and carcinomatous human prostate gland.** *Exp Mol Pathol* 8:216-24, 1968.

Farnsworth WE et al. **Interaction of prolactin and testosterone in the human prostate.** *Urol Res* 9:79-88, 1981.

Judd AM et al. **Zinc acutely, selectively and reversibly inhibits pituitary prolactin secretion.** *Brain Res* 294:190-2, 1984.

Leake A et al. **Interaction between prolactin and zinc in the human prostate gland.** *J Endocrinol* 102(1):73-6, 1984.

Leake A et al. **The effect of zinc on the 5-alpha-reduction of testosterone by the hyperplastic human prostate gland.** *J Steroid Biochem* 20:651-5., 1984.

Fahim MS et al. **Zinc treatment for the reduction of hyperplasia of the prostate.** *Fed Proc* 35:36, 1976.

Zaichick VY, Sviridova TV, Zaichick SV. **Zinc concentration in human prostatic fluid: normal, prostatitis, adenoma and cancer.** *Int Urol Nephrol* 28(5):687-94, 1996.

Werbach MR. **Nutritional Influences on Illness: a sourcebook of clinical research, 2nd Ed.** *Third Line Press, Tarzana Calif.* 1993.

Harris ED. **Cellular copper transport and metabolism.** *Annu Rev Nutr.* 20:291-310, 2000.

Niederprum HJ, Schweikert HU, Zanker KS. **Testosteron 5D-reductase inhibition by free fatty acids from Sabal serrulata fruits.** *Phytomedicine,* 1:127-133, 1994.

Plosker GL, Brogden RN. **Serenoa repens (Permixon ®): A review of its pharmacological and therapeutic efficacy in benign prostatic hyperplasia.** *Drugs & Aging* 9(5):379-395, 1996.

Ravenna L et al. **Effects of the lipidosterolic extract of Serenoa repens (Permixon ®) on human prostatic cell lines.** *Prostate* 29(4):219-230, 1996.

Wilt TJ et al. **Saw palmetto extracts for treatment of benign prostatic hyperplasia – A systematic review.** *JAMA* 280:1604-9, 1998.

Gerber GS et al. **Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms.** *Urology* 51:1003-7, 1998.

Koch E, Biber A. **Pharmacological effects of Sabal and urtica extracts as basis for a rational medication of benign prostatic hyperplasia.** *Urologe* 34:90-5, 1994.

Champault G, et al. **A double blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia.** *Br J Clin Pharmacol,* Sept;18(3):461-462, 1984.

Klippel KF, Hiltl DM, Schipp B. **A multicentric, placebo-controlled, double-blind clinical trial of beta sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia.** *Br J Urol* 80:427-32, 1997.

Berges RR, Windeler J, Trampisch HJ, Senge TH. **Randomised, placebo-controlled, double-blind clinical trial of B-Sitosterol in patients with benign prostatic hyperplasia.** *Lancet* 345:1529-32, 1995.

Andro M-C, Riffaud J-P. **Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience.** *Curr Ther Res* 56:796-817, 1995.

Werbach MR, Murray MT. **Botanical Influences on Illness: A Sourcebook of Clinical Research, 2nd Ed.** *Third Line Press, Inc., Tarzana, Calif.* 2000.

Gann PH, Ma J, Giovannucci E, et al. **Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis.** *Cancer Res.* 59:1225-1230, 1999.

Giovannucci E. **Tomatoes, tomato-based products, lycopene, and cancer: Review of the epidemiologic literature.** *J Natl Cancer Inst.* 87:1767-1976, 1995.

Sengupta A, Das S. **The anti-carcinogenic role of lycopene, abundantly present in tomato.** *Eur J Cancer Prev.* 8:325-330, 1999.

Sies H, Stahl W. **Lycopene: antioxidant and biological effects and its bioavailability in the human.** *Proc Soc Exp Biol Med.* 218:121-124, 1998.

Kucuk, O et al. **Lycopene supplementation in men with prostate cancer (PCa) reduces grade and volume of preneoplasia (PIN) and tumor, decreases serum PSA and modulates biomarkers of growth and differentiation.** *Karmanos Cancer Institute, Wayne State University, Detroit, MI,* 1999.

Levy j, Bosin E, Feldin B, Giat Y, Minsler A, Danilenko M, Sharoni Y. **Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene.** *Nutr Cancer,* 24(3):257-66, 1995.

PDR for Nutritional Supplements, 1st Ed. *Medical Economics/Thompson Healthcare,* 2001.

PDR for Herbal Medicines, 1st Ed. *Medical Economics/Thompson Healthcare,* 1998.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

*For Quality and Value without
Compromise*



Is the logical choice!